LeaderPortfolio
Rubiralta
Marc Rubiralta
Rank #2934
SPAINHealthcareDiagnostics

Marc Rubiralta

Net Worth
$1.285B
0% (24h)
Marc Rubiralta, a Spanish billionaire, is a key figure in the diagnostics industry. As the chair of Werfen, a leading in-vitro diagnostics company, he inherited his stake from his father, who founded the company in 1966. With a current net worth of $1.3 billion, his wealth stems from the healthcare sector, specifically from Werfen. Rubiralta's career has involved strategic acquisitions, including the $2 billion purchase of U.S.-based Immucor. His leadership has been instrumental in Werfen's growth and its role in diagnostics.

The Full Dossier

Early Life and Background

Marc Rubiralta is a Spanish billionaire. His father, José María Rubiralta, founded Werfen in 1966 as a distributor of medical supplies. Werfen evolved into a global leader in in-vitro diagnostics.

Rise to Success

Marc Rubiralta, along with his brothers, owns and runs Werfen. He became the chairman of Werfen in 2019. One of his significant strategic moves was the $2 billion acquisition of U.S.-based Immucor. His leadership has contributed to the company's position in the diagnostics market. He also co-owns the Celsa Group, one of Spain's largest industrial groups.

Key Business Strategies

Werfen's growth strategy involved acquiring companies such as Tem and Accriva Diagnostics. Werfen's success is rooted in its ability to produce high-quality diagnostics. Marc Rubiralta has also been involved in expanding the company commercially in the United States and China.

Philanthropy

Information about Marc Rubiralta's specific philanthropic activities could not be found.

Career Timeline

2019

Acquisition of Immucor

Oversaw the $2 billion acquisition of the U.S.-based Immucor.

2019

Chairman of Werfen

Appointed Chairman of Werfen, a leading in-vitro diagnostics company.

Philanthropic Impact

UnknownUndisclosed

Unknown

Philanthropic activities are not specified.

Wealth Trajectory